| Cat.No. | Name | Information |
|---|---|---|
| M1744 | ARRY-162 (Binimetinib) | ARRY-162 (MEK-162; Binimetinib) is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively. |
| M1759 | GSK1120212 (Trametinib) | Trametinib (GSK1120212; Jtp-74057) is an orally effective MEK inhibitor with IC50 of 2 nM against MEK1 and MEK2, respectively. Trametinib can activate autophagy and induce apoptosis. |
| M1763 | Mirdametinib (PD0325901) | Mirdametinib (PD0325901) is a highly potent and selective MEK inhibitor with an IC50 in C26 cells of 0.33nM. |
| M1977 | U0126-EtOH | U0126-EtOH is a potent and highly selective non-competitive inhibitor of MAPK/ERK kinase with IC50 of 72 nM for MEK1 and 58 nM for MEK2. |
| M3626 | Cobimetinib (GDC-0973) | Cobimetinib (GDC-0973, RG7420) is an effective, selective, oral MEK1 inhibitor with an IC50 of 4.2 nM against MEK1. In addition, Cobimetinib is an inhibitor of Akt. |
| M1661 | AZD6244 | AZD6244 (ARRY-142886, Selumetinib) is a potent MEK 1/2 inhibitor with GI50 values ranging from 14 to 50 nM. |
| M1822 | PD98059 | PD98059 is a potent and selective inhibitor of mitogen-activated protein kinase kinase (MKK / MEK) with IC50 value of 2-7 μM. The expression of KAT2B protein in cells is significantly decreased after PD98059 inhibits ERK signaling pathway. |
| M14169 | GDC-0623 | GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM). |
| M1750 | TAK-733 | TAK-733 is a potent and selective MEK allosteric site inhibitor with IC50 of 3.2nM for the treatment of cancer. |
| M1690 | CI-1040 | CI-1040 (PD184352) is a targeted signal transduction inhibitor of MEK with a ki value of 300nM in vitro. |
| M1662 | AZD8330 | AZD8330 (ARRY-424704) is a novel, selective, highly efficacious, uncompetitive MEK inhibitor with an IC50 of 7 nM. |
| M1652 | AS703026 | AS703026 is a novel selective MEK1/2 inhibitor, and induces pleiotropic anti-myeloma activity in vitro and in vivo. |
| M49731 | Glycinexylidide | Glycinexylidide (GX) is the active metabolite of Lidocaine. |
| M49725 | Xantocillin | Xantocillin (Xanthocillin X) is a marine agent extracted from Penicillium commune, induces autophagy through inhibition of the MEK/ERK pathway. |
| M42145 | MEK-IN-6 hydrate | MEK-IN-6 hydrate is a MEK inhibitor. |
| M42144 | MS934 | MS934 is a novel improved VHL-recruiting MEK 1/2 degrader. |
| M42143 | Nedometinib | Nedometinib is a tyrosine kinase inhibitor targeting to MEK1. |
| M42142 | GW284543 hydrochloride | GW284543 (UNC10225170) hydrochloride is a selective MEK5 inhibitor. |
| M42141 | Trametiglue | Trametiglue, a derivative of Trametinib, targets both KSR-MEK and RAF-MEK with unprecedented potency and selectivity via unique interfacial binding interactions. |
| M30350 | E6201 | E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC50 value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC50 value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC50 value of 19 nM. Anti-tumor and anti-psoriasis efficacy. |
| M29856 | MEK-IN-4 | MEK-IN-4 is a MEK inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers. |
| M29098 | APS-2-79 | APS-2-79 is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATPbiotin binding to KSR2 within the KSR2-MEK1 complexe with an IC50 of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling. |
| M28882 | EBI-1051 | EBI-1051 is a highly potent and orally efficacious MEK inhibitor with an IC50 of 3.9 nM. |
| M27786 | U0126 | U0126 is a potent, non-ATP-competitive, selective inhibitor of MEK1 and MEK2 with IC50s of 72 nM and 58 nM, respectively.In addition, U0126 is an autophagy and mitophagy inhibitor and inhibits LPA-induced entosis. |
| M21987 | Cobimetinib racemate | Cobimetinib racemate is the racemate of Cobimetinib, a potent, selective, orally available MEK1 inhibitor with an IC50 for MEK1 inhibition of 4.2 nM.In addition, Cobimetinib is an Akt inhibitor. |
| M21071 | MAP855 | MAP855 is a potent, selective and orally effective ATP-competitive MEK1/2 kinase inhibitor (MEK1 ERK2 cascade IC50=3 nM, pERK EC50=5 nM). MAP855 inhibits wild-type and mutant MEK1/2 equally. |
| M20028 | WAY-114228 | WAY-114228 is a MEK1 inhibitor. |
| M14171 | Selumetinib sulfate | Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
